sglt2 inhibitors vs glp 1 Cardiorenal Protection: Potential of and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes | Diabetes Therapy SGLT2 inhibitors-what do guidelines say?

Breastfeeding Breastfeeding women should be cautious about taking GLUTONE INJECTION 1

89 In addition to ONOO -mediated oxidation of BH 4 , there may be also an intracellular decrease because of decreased synthesis by inhibition of the GTP cyclohydrolase I ( de novo synthetic pathway) or by inhibition of the so-called salvage pathway involving enzymes such as the sepiapterin synthase, the sepiapterin reductase or the dihydrofolate reductase

These risks are not being adequately communicated to patients, and shockingly, they are not listed in the official warning labels for most GLP-1 drugs

Sitagliptin has been demonstrated to increase plasma PYY 136 :PYY 336 ratios in T2D patients, indicating that PYY is a physiological substrate for DPP-IV 47